Physician profile
Ayan Sanyal
NPI 1417211145
$2,301.71
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,248 · 2020: $581 · 2021: $455 · 2022: $17.79.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $451.90 | 2019-2021 | |
| Novo Nordisk INC | $306.09 | 2019-2021 | |
| Amgen INC. | $246.31 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $169.78 | 2019 | |
| Pfizer INC. | $165.96 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.06 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $134.14 | 2019-2021 | |
| Lilly USA, LLC | $81.97 | 2019-2021 | |
| Mylan Specialty L.P. | $63.20 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $62.16 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.98 | 2019-2020 | |
| Allergan, INC. | $48.97 | 2019-2020 | |
| Abbvie INC. | $46.77 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.40 | 2019-2021 | |
| Sanofi Pasteur INC. | $39.93 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $36.27 | 2020 | |
| Astellas Pharma US INC | $35.88 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $32.99 | 2021 | |
| Genentech USA, INC. | $22.73 | 2019 | |
| Daiichi Sankyo INC. | $20.13 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $17.23 | 2020 | |
| Arbor Pharmaceuticals, INC. | $16.10 | 2019 | |
| Hologic Sales and Service, LLC | $12.87 | 2021 | |
| Almatica Pharma LLC | $11.76 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.63 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.50 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayan Sanyal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.